HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...

Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with ...

As many as a quarter of all Americans carry at least one copy of the APOE-e4 gene, but more than half of reported Alzheimer’s ...

Expanding bispecific antibody access for multiple myeloma involves collaboration between academic centers and community ...

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler, more ...

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of months. In ...

A new study presents robust evidence on the role of lysophosphatidylcholines (LPCs) in the onset of Alzheimer's disease.

A new study presents robust evidence on the role of lysophosphatidylcholines (LPCs) in the onset of Alzheimer's disease. Researchers discovered that LPCs-compounds that transport a variety of healthy ...

No one can tell you exactly how long you will live. Below are general statistics based on large groups of people. Remember, they can’t tell you what will happen in your individual case. Your doctor ...